Search Result

Results for "

Ischemic stroke

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Akt (8) AMPK (1) Apoptosis (16) Aquaporin (1) ASK1 (2) Bacterial (2) Bcl-2 Family (3) Biochemical Assay Reagents (3) Calcium Channel (3) Caspase (5) CaSR (2) Cathepsin (1) Collagen (1) COX (2) Cytochrome P450 (2) Drug Derivative (2) Endogenous Metabolite (3) Endoplasmic Reticulum Oxidoreductase 1 (ERO1) (1) Endothelin Receptor (1) Epigenetic Reader Domain (1) ERK (1) Ferroptosis (3) FOXO (1) Fungal (1) GABA Receptor (1) Glutathione Peroxidase (1) Glycoprotein VI (1) GSK-3 (1) GSNOR (2) Heme Oxygenase (HO) (1) HSP (2) iGluR (7) Integrin (2) Interleukin Related (4) Isotope-Labeled Compounds (3) Keap1-Nrf2 (7) Ligands for Target Protein for PROTAC (1) Liposome (1) MDM-2/p53 (1) mGluR (1) Mixed Lineage Kinase (3) MMP (2) mTOR (1) nAChR (2) Necroptosis (1) NF-κB (1) NO Synthase (5) NOD-like Receptor (NLR) (2) Opioid Receptor (1) P2X Receptor (4) P2Y Receptor (2) p38 MAPK (1) PGC-1α (2) Phosphodiesterase (PDE) (1) Phospholipase (3) PI3K (5) Potassium Channel (2) PPAR (1) Prostaglandin Receptor (5) Pyroptosis (2) Quinone Reductase (1) Reactive Oxygen Species (ROS) (9) Reference Standards (5) RIP kinase (4) ROCK (1) SARS-CoV (1) Ser/Thr Protease (2) Sirtuin (1) Sodium Channel (3) TGF-beta/Smad (2) Thrombin (1) TNF Receptor (1) Toll-like Receptor (TLR) (2) TRP Channel (8)
By Research Areas:	Cancer (9) Cardiovascular Disease (37) Endocrinology (4) Infection (2) Inflammation/Immunology (21) Metabolic Disease (5) Neurological Disease (75)
Oligonucleotides:	Cationic Lipids (1)

101

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Gavestinel sodium salt GV 150526A	iGluR	Cardiovascular Disease
Gavestinel (GV 150526A) is a potent, selective, orally active and non-competitive antagonist of NMDA receptor. Gavestinel binds to the glycine site of the NMDA receptor, with a pK_i of 8.5. Gavestinel can be used for the research of acute ischemic stroke .

AER-271 1 Publications Verification	Aquaporin	Cardiovascular Disease Neurological Disease
AER-271, a phosphonate proagent derivative of AER-270, is an aquaporin-4 (AQP4) inhibitor for the research of acute ischemic stroke .

Neuroprotective agent 4	Others	Neurological Disease
Neuroprotective agent 4 (compound 24a) is a novel and effective small molecule antioxidant. Neuroprotective agent 4 has a neuroprotective effect. Neuroprotective agent 4 can be used in the study of ischemic stroke and related diseases .

Edaravone dimer impurity	Drug Derivative	Neurological Disease
Edaravone dimer impurity (Dimer 2) is a stable conjugated Edaravone (HY-B0099) dimer. Edaravone is a free radical scavenging agent for the study of acute ischemic stroke .

Thrombin-cleavable peptide	Thrombin	Cardiovascular Disease Neurological Disease
Thrombin-cleavable peptide is a type of peptide that can be recognized and cleaved by thrombin. After cleavage, Thrombin-cleavable peptide releases thrombolytic peptides to initiate thrombolysis. Thrombin-cleavable peptide can be used in the research of diseases such as ischemic stroke .

MRS4596	P2X Receptor	Neurological Disease
MRS4596 is a potent and selective P2X4 receptor antagonist with an IC₅₀ value of 1.38 μM for human P2X4 receptor. MRS4596 has neuroprotective and neuro-rehabilitative activities in ischemic stroke model. MRS4596 can be used in research of ischemic stroke .

MLN2201 YFC51.1; LDP-01	Integrin	Inflammation/Immunology
MLN2201 is a humanized monoclonal antibody inhibitor, targeting Integrin β2. MLN2201 inhibits the reperfusion injury after stroke and can be used for inflammatory diseases like ischemic stroke research .

TRC051384 hydrochloride	HSP	Cardiovascular Disease Neurological Disease
TRC051384 hydrochloride is a potent inducer of heat shock protein 70 (HSP70). TRC051384 hydrochloride exhibits protective effects against neuronal trauma via inhibition of necroptosis. TRC051384 hydrochloride can be used for the research of ischemic stroke .

GABA-A Receptor Ligand-1	GABA Receptor	Neurological Disease
GABA-A Receptor Ligand-1 (Compound 4) is a ligand for GABA-A receptor with a pK_i of 7.27. GABA-A Receptor Ligand-1 reduces mitochondrial dysfunction, promotes neurite outgrowth and neuronal regeneration. GABA-A Receptor Ligand-1 exhibits neuroprotective efficacy in rats ischemic stroke models .

ATF3-IN-1	Ferroptosis Epigenetic Reader Domain Reactive Oxygen Species (ROS) Glutathione Peroxidase	Cardiovascular Disease Neurological Disease
ATF3-IN-1 is a ferroptosis and ATF3 inhibitor. ATF3-IN-1 inhibits oxidative stress and ferroptosis through the ATF3/SLC7A11/GPX4 pathway, exerting anti-ischemic stroke effects. ATF3-IN-1 can attenuate ischemia/reperfusion (I/R) injury and improve neuronal survival. ATF3-IN-1 has neuroprotective effects and can be used to study ischemic stroke .

TAT-EE3	TRP Channel iGluR Calcium Channel	Neurological Disease
TAT-EE3 is a neuroprotective peptide which can uncouple TRPM2-NMDARs interaction. TAT-EE3 inhibits TRPM2-induced enhancement of NMDAR surface expression and current amplitude.TAT-EE3 protects neurons against ischemic injury in vitro and in vivo. TAT-EE3can be used for the study of ischemic stroke .

Neuroprotective agent 1	Drug Derivative	Cardiovascular Disease
Neuroprotective agent 1 (2), a promising neuroprotective agent for the study of ischemic stroke, shows promising neuroprotective activity with the EC₅₀ value of 16.07 μM in the model of glutamate-induced excitotoxicity and 19.30 μM in the model of H₂O₂-induced oxidative damage .

GSNOR-IN-2	GSNOR	Neurological Disease
GSNOR-IN-2 (Compound 45) is a S-nitrosoglutathione reductase (GSNOR) inhibitor with an IC₅₀ of 44.12 nM. GSNOR-IN-2 has neuroprotective activity, promising for ischemic stroke research .

OY-201	Others	Neurological Disease
OY-201 is a potential and BBB-penetrated anti-ischemic stroke agent. OY-201 shows the good safety and neuroprotective activity in both in vitro and in vivo models .

MRS4719	P2X Receptor	Neurological Disease
MRS4719 is a potent P2X4 receptor antagonist with an IC₅₀ value of 0.503 μM for human P2X4 receptor. MRS4719 can reduce infarct volume and reduce brain atrophy, showing neuroprotective and neuro-rehabilitative activities in ischemic stroke model. MRS4719 also reduces ATP-induced [Ca ²⁺]_i influx in primary human monocyte-derived macrophages. MRS4719 can be used to research ischemic stroke .

Cinepazide	Calcium Channel	Cardiovascular Disease
Cinepazide is a piperazine derivative and acts as a weak calcium channel blocker. Cinepazide is a potent vasodilator and can be used for the research of cerebrovascular diseases, including ischemic stroke, brain infarct et. al .

LY836	iGluR	Neurological Disease
LY836 is an orally active neuroprotective agent. LY836 significantly blocks PSD95-nNOS association in cortical neurons. LY836 can be used in study ischemic stroke .

α5β1 integrin agonist-2	Integrin Akt ERK	Cardiovascular Disease
α5β1 integrin agonist-2 (Compound 2) is a highly selective α5β1 integrin agonist (EC₅₀=45.98 nM). α5β1 integrin agonist-2 enhances extracellular matrix adhesion and Akt/ERK signaling activation. α5β1 integrin agonist-2 is promising for research of ischemic stroke .

Cinepazide Maleate MD-67350	Calcium Channel	Cardiovascular Disease
Cinepazide Maleate (MD-67350) is a piperazine derivative and acts as a weak calcium channel blocker. Cinepazide Maleate is a potent vasodilator and can be used for the research of cerebrovascular diseases, including ischemic stroke, brain?infarct et. al .

NPB-1575	Ferroptosis Keap1-Nrf2 NF-κB FOXO NO Synthase Quinone Reductase	Neurological Disease Inflammation/Immunology
NPB-1575 is a potent, orally active and brain-penetrant anti-inflammatory agent. NPB-1575 mitigates neuroinflammation and resists ferroptosis by activating the IRS2/Nrf2/NF-κB axis. NPB-1575 shows protective effect against cerebral ischemic injury and improves the neurological functional prognosis. NPB-1575 can be used for the study of ischemic stroke .

Tat-NTS peptide	Apoptosis	Neurological Disease
Tat-NTS peptide is a cell-penetrating peptide with neuroprotective effects. Tat-NTS peptide can specifically inhibit the nuclear translocation of ANXA1 and reduce neuronal apoptosis in ischemic areas. Moreover, Tat-NTS peptide can reduce the volume of cerebral ischemic infarction and can be used in the research of ischemic stroke .

NT1-014B	Liposome Biochemical Assay Reagents	Cardiovascular Disease Neurological Disease
NT1-014B is a tryptamine-derived lipidoid. NT1-014B incorporates NT-lipidoid into BBB-impermeable lipid nanoparticles (LNPs), enabling the LNPs to cross the BBB. NT1-014B enhances brain delivery via intravenous injection. NT1-014B can be used in ischemic stroke research .

TRPM2-IN-1	TRP Channel	Neurological Disease
TRPM2-IN-1 (compound D10) is a potent TRPM2 inhibitor. TRPM2-IN-1 exhibits antistroke activity and significant neuroprotective effect. TRPM2-IN-1 can be used in the study of ischemic stroke .

A2A/A1 AR antagonist-1	Adenosine Receptor	Neurological Disease
A2A/A1 AR antagonist-1 (compound 1a) is dual potent A_2A/A₁ AR antagonist with K_is of 5.58 and 24.2 nM, respectively. A2A/A1 AR antagonist-1 has the potential for the research of ischemic stroke .

(S)-Oxiracetam (S)-(-)-Oxiracetam; (S)-ISF2522	Apoptosis	Neurological Disease
(S)-oxiracetam (S-ORC) is an inhibitor targeting apoptosis. S-ORC reduces brain infarct size and lessens neurological dysfunction in middle cerebral artery occlusion/reperfusion (MCAO/R) models. S-ORC prevents neuronal apoptosis via activating PI3K/Akt/GSK3β signaling pathway via α7 nAChR after ischemic stroke. S-ORC can prevent neuronal death after ischemic stroke .

MG1 peptide	Biochemical Assay Reagents	Neurological Disease
MG1 peptide is a M1 Microglia-targeting peptide. MG1 peptide can conjugate to anoparticles, crossing the BBB to precisely M1 microglia recognition and achieving controlled release and specific accumulation of drugs through intelligent molecular switching. MG1 peptide can be used for drug delivery for ischemic stroke research .

RIPK1-IN-33	RIP kinase Ferroptosis	Neurological Disease
RIPK1-IN-33 is a blood-brain barrier-permeable and orally active RIPK1 inhibitor, with an IC₅₀ of 0.115 μM. RIPK1-IN-33 demonstrates remarkable anti-ferroptosis activity, radical scavenging capacity (IC₅₀ = 123.3 μM), and anti-lipid peroxidation effects (IC₅₀ = 9.72 μM). RIPK1-IN-33 markedly reduces cerebral infarction volume and improves neurological function scores in transient middle cerebral artery occlusion (tMCAO) model. RIPK1-IN-33 can be used for the study of ischemic stroke .

M6766	Endoplasmic Reticulum Oxidoreductase 1 (ERO1) Reactive Oxygen Species (ROS)	Cardiovascular Disease Neurological Disease
M6766 is a selective endoplasmic reticulum oxidoreductase 1α (ERO1α) inhibitor with an IC₅₀ of 1.4 μM and a K_D of 1.1 μM. M6766 also inhibits ERO1β with an IC₅₀ of 7.2 μM. M6766 binds to the flavin adenine dinucleotide-binding pocket in ERO1α. M6766 inhibits granule secretion, αIIbβ3 integrin activation, Ca ²⁺ mobilization, and platelet aggregation. M6766 can be used for the research of neurological disease, such as ischemic stroke .

LK-2	Sodium Channel	Neurological Disease
LK-2 is an antagonist for ASIC1a with a K_d of 1.9 μM. LK-2 reduces glutamate-induced ASIC1a current-enhancement with an IC₅₀ of 6.6 μM. LK-2 exhibits neuroprotective efficacy in mouse ischemic stroke model, with improved motor and coordination skills. LK-2 is blood-brain barrier (BBB) penetrable .

Ligustroflavone 1 Publications Verification Nuezhenoside	CaSR RIP kinase Mixed Lineage Kinase TGF-beta/Smad	Cardiovascular Disease Neurological Disease Metabolic Disease Endocrinology
Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis .

TAN-67 dihydrobromide SB-205607 dihydrobromide	Opioid Receptor	Neurological Disease
TAN-67 (SB-205607) dihydrobromide is a potent and selective nonpeptidic δ-opioid receptor agonist with a K_i value of 0.647 nM. TAN-67 dihydrobromide has neuroprotective effect. TAN-67 dihydrobromide can be used in research of ischemic stroke .

MDL-811	Sirtuin Interleukin Related Cytochrome P450	Neurological Disease Inflammation/Immunology Cancer
MDL-811 is a selective allosteric activator of SIRT6 with an EC₅₀ of 5.7 μM. MDL-811 possesses anti-inflammatory, antitumor, and neuroprotective activities. MDL-811 can be used for the research of diseases such as colorectal cancer and ischemic stroke .

GSNOR-IN-1	GSNOR Apoptosis	Neurological Disease
GSNOR-IN-1, a prodrug of GSNOR-IN-2 (HY-176275), is a BBB-penetrable S-nitrosoglutathione reductase (GSNOR) inhibitor. GSNOR-IN-1 has significant protective activity against OGD/R-induced injury. GSNOR-IN-1 regulates calcium signaling and synaptic function via Clstn1 S-nitrosation and inhibits neuronal apoptosis. GSNOR-IN-1 significantly reduces infarct volume while improving neurological deficits in ischemic stroke rat models. GSNOR-IN-1 has neuroprotective activity, promising for ischemic stroke research .

Nrf2 activator 19	Keap1-Nrf2 Apoptosis Reactive Oxygen Species (ROS)	Cardiovascular Disease
Nrf2 activator 19 is a BBB-penetrable NRF2/HO-1 activator. Nrf2 activator 19 exerts potent antioxidant and neuroprotective effects. Nrf2 activator 19 can also effectively reduce brain damage, reduce Reactive Oxygen Species (ROS) accumulation. Nrf2 activator 19 inhibits neuronal apoptosis. Nrf2 activator 19 promotes the recovery of neurological function and motor ability. Nrf2 activator 19 shows significant potential in ischemic stroke research .

FIPI 4 Publications Verification 5-Fluoro-2-indolyl deschlorohalopemide	Phospholipase	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
FIPI is a phospholipase D (PLD) inhibitor with an IC₅₀ for PLD1 and PLD2 of about 25 nM. FIPI regulates cytoskeletal recombination, cell diffusion and chemotaxis. FIPI can be used in cancer research. In addition, FIPI can enhance the secretion and aggregation of platelet dense particles, inhibit thrombosis, reduce ischemic stroke infarct volume and improve nerve function .

DB-10	p38 MAPK	Neurological Disease
DB-10 is a pro-agent of 3-nbutylphthalide (NBP) (HY-B0647). DB-10 has significantly high uptake ability via pyrilamine cationic transporters in the temperature and energy dependent manner in cells. DB-10 improves the survival rate of cells. DB-10 could rapidly convert into active original agent and increase the accumulation in the brain in vivo. DB-10 can be used for ischemic stroke study .

TAT-CIRP	Toll-like Receptor (TLR)	Neurological Disease
TAT-CIRP is a a small peptide, refers to Trans-trans-activating (Tat)-cold-inducible RNA binding protein. TAT-CIRP is an inhibitor of myeloid differentiation protein 2 (MD2). TAT-CIRP exhibits robust neuroprotection against ischemic and hemorrhagic stroke in mice .

Tat-ASIC1a (1-20) (mouse, rat)	Sodium Channel RIP kinase	Neurological Disease
Tat-ASIC1a (1-20) (mouse, rat) is a competitive ASIC1a membrane-penetrating peptide. Tat-ASIC1a (1-20) (mouse, rat) has significantly neuroprotection effects, and reduces neuronal damage against acidotoxicity by targeting the ASIC1a-RIPK1 pathway and auto-inhibitory mechanism. Tat-ASIC1a (1-20) (mouse, rat) effectively protects brains from ischemic injury in ischemic stroke mice model. Tat-ASIC1a (1-20) (mouse, rat) can be used for neurodegenerative diseases research, such as Huntington disease and Parkinson’s disease .

P2Y1 antagonist 4	P2Y Receptor Keap1-Nrf2	Cardiovascular Disease Neurological Disease
P2Y1 antagonist 4 is a selective P2Y1 receptor antagonist with excellent blood-brain barrier (BBB) penetration. P2Y1 antagonist 4 inhibits P2Y1 receptor-mediated cytosolic Ca ²⁺ increase (IC₅₀ = 1.95 μM) and platelet aggregation (IC₅₀ = 3.24 μM) induced by ADP in rabbit washed platelets. P2Y1 antagonist 4 significantly upregulates the level of nuclear Nrf2 protein in H2O2-treated HT22 cells. P2Y1 antagonist 4 reduces myocardial infarct size in a mouse acute myocardial infarction (MI) model. P2Y1 antagonist 4 can be used for the study of ischemic stroke and myocardial infarction .

Kv2.1-IN-1 1 Publications Verification	Potassium Channel Apoptosis	Cardiovascular Disease Neurological Disease
Kv2.1-IN-1 is an orally active and blood-brain barrier penetrant Kv2.1 inhibitor with an IC₅₀ of 0.07 μM. Kv2.1-IN-1 exhibits a selectivity >130 fold over other K ⁺, Na ⁺, and Ca ²⁺ ion channels. Kv2.1-IN-1 decreases the apoptosis of HEK293 cells induced by H₂O₂. Kv2.1-IN-1 produces significant neuroprotection efficacy in middle cerebral artery occlusion (MCAO) rat. Kv2.1-IN-1 can be used for the study of ischemic stroke .

PSD-95/nNOS PPI-IN-1	iGluR NO Synthase Apoptosis Reactive Oxygen Species (ROS)	Neurological Disease
PSD-95/nNOS PPI-IN-1 is a inhibitor targeting the PSD-95/nNOS interaction with potential blood-brain barrier penetration. PSD-95/nNOS PPI-IN-1 binds to the PSD-95 PDZ2 domain with high affinity (K_i = 19.45 μM). PSD-95/nNOS PPI-IN-1 inhibits glutamate-induced excitotoxicity by reducing intracellular ROS levels and inhibiting apoptosis. PSD-95/nNOS PPI-IN-1 significantly reduces cerebral infarct volume in rat tMCAO models. PSD-95/nNOS PPI-IN-1 can be used for the study of acute ischemic stroke .

Fenazinel dihydrochloride	iGluR	Neurological Disease
Fenazinel dihydrochloride, an N-methyl-D-aspartate (NMDA) receptor antagonist, shows promise as a potential treatment for ischemic stroke.

ZD-1611	Endothelin Receptor	Cardiovascular Disease Endocrinology
ZD-1611 is a potent, orally active, selective ETA receptor antagonist, used for the research of ischemic stroke.

2-(1-Hydroxypentyl)benzoic acid	Endogenous Metabolite	Neurological Disease
2-(1-Hydroxypentyl)benzoic acid is a compound being explored for its potential use in the treatment of acute ischemic stroke (AIS).

CHIR 98024	GSK-3	Neurological Disease
CHIR 98024 (Compound L) is a glycogen synthase kinase 3 (GSK3) inhibitor with an EC₅₀ of 0.2566 μM .

Cat. No.	Product Name	Type

HY-137500

NT1-014B	Drug Delivery
NT1-014B is a tryptamine-derived lipidoid. NT1-014B incorporates NT-lipidoid into BBB-impermeable lipid nanoparticles (LNPs), enabling the LNPs to cross the BBB. NT1-014B enhances brain delivery via intravenous injection. NT1-014B can be used in ischemic stroke research .

HY-NP001

Cationic Bovine Serum Albumin

1 Publications Verification

CBSA

Native Proteins

Cationic Bovine Serum Albumin is a bovine serum albumin (BSA) modified with excess ethylenediamine, which has enhanced immunogenicity compared to native BSA. Positively charged primary amines block all negatively charged carboxyl groups, making Cationic Bovine Serum Albumin a cationic protein. Cationic Bovine Serum Albumin has remarkable neuroprotective effects on ischemic stroke when in combination with Tanshinone IIA (HY-N0135) .

Cat. No.	Product Name	Target	Research Area

HY-P10275

Tat-NTS peptide	Apoptosis	Neurological Disease
Tat-NTS peptide is a cell-penetrating peptide with neuroprotective effects. Tat-NTS peptide can specifically inhibit the nuclear translocation of ANXA1 and reduce neuronal apoptosis in ischemic areas. Moreover, Tat-NTS peptide can reduce the volume of cerebral ischemic infarction and can be used in the research of ischemic stroke .

HY-P5883

TAT-M2NX tatM2NX	TRP Channel	Neurological Disease
TAT-M2NX (tatM2NX) is a TRPM2 inhibitor with specific neuroprotective activity in male mice. TAT-M2NX can be used to study ischemic neuronal damage .

HY-P11049

Stroke-homing peptide	Peptides	Neurological Disease
Stroke-homing peptide is a homing peptide. Stroke-homing peptide can home to ischemic stroke brain tissue and detect the apoptotic neuronal cells. Stroke-homing peptide can be used for the research of molecular imaging and selective drug delivery to stroke tissue .

HY-P11048

Thrombin-cleavable peptide	Thrombin	Cardiovascular Disease Neurological Disease
Thrombin-cleavable peptide is a type of peptide that can be recognized and cleaved by thrombin. After cleavage, Thrombin-cleavable peptide releases thrombolytic peptides to initiate thrombolysis. Thrombin-cleavable peptide can be used in the research of diseases such as ischemic stroke .

HY-P11117

TAT-EE3	TRP Channel iGluR Calcium Channel	Neurological Disease
TAT-EE3 is a neuroprotective peptide which can uncouple TRPM2-NMDARs interaction. TAT-EE3 inhibits TRPM2-induced enhancement of NMDAR surface expression and current amplitude.TAT-EE3 protects neurons against ischemic injury in vitro and in vivo. TAT-EE3can be used for the study of ischemic stroke .

HY-P11315

MG1 peptide	Biochemical Assay Reagents	Neurological Disease
MG1 peptide is a M1 Microglia-targeting peptide. MG1 peptide can conjugate to anoparticles, crossing the BBB to precisely M1 microglia recognition and achieving controlled release and specific accumulation of drugs through intelligent molecular switching. MG1 peptide can be used for drug delivery for ischemic stroke research .

HY-P5117

TAT-CIRP	Toll-like Receptor (TLR)	Neurological Disease
TAT-CIRP is a a small peptide, refers to Trans-trans-activating (Tat)-cold-inducible RNA binding protein. TAT-CIRP is an inhibitor of myeloid differentiation protein 2 (MD2). TAT-CIRP exhibits robust neuroprotection against ischemic and hemorrhagic stroke in mice .

HY-P10977

Tat-ASIC1a (1-20) (mouse, rat)	Sodium Channel RIP kinase	Neurological Disease
Tat-ASIC1a (1-20) (mouse, rat) is a competitive ASIC1a membrane-penetrating peptide. Tat-ASIC1a (1-20) (mouse, rat) has significantly neuroprotection effects, and reduces neuronal damage against acidotoxicity by targeting the ASIC1a-RIPK1 pathway and auto-inhibitory mechanism. Tat-ASIC1a (1-20) (mouse, rat) effectively protects brains from ischemic injury in ischemic stroke mice model. Tat-ASIC1a (1-20) (mouse, rat) can be used for neurodegenerative diseases research, such as Huntington disease and Parkinson’s disease .

HY-175824

PSD-95/nNOS PPI-IN-1	iGluR NO Synthase Apoptosis Reactive Oxygen Species (ROS)	Neurological Disease
PSD-95/nNOS PPI-IN-1 is a inhibitor targeting the PSD-95/nNOS interaction with potential blood-brain barrier penetration. PSD-95/nNOS PPI-IN-1 binds to the PSD-95 PDZ2 domain with high affinity (K_i = 19.45 μM). PSD-95/nNOS PPI-IN-1 inhibits glutamate-induced excitotoxicity by reducing intracellular ROS levels and inhibiting apoptosis. PSD-95/nNOS PPI-IN-1 significantly reduces cerebral infarct volume in rat tMCAO models. PSD-95/nNOS PPI-IN-1 can be used for the study of acute ischemic stroke .

HY-P3012

Cathepsin G	Cathepsin	Inflammation/Immunology
Cathepsin G acts as a potent agonist of human platelet activation leading to their aggregation., and can be used for screening of relevant inhibitors .

HY-P5754

TAT-NEP1-40	Apoptosis	Neurological Disease
TAT-NEP1-40 is a BBB-penatrable peptide. TAT-NEP1-40 protects PC12 cells against oxygen and glucose deprivation (OGD), and promotes neurite outgrowth. TAT-NEP1-40 also improves ischemia-induced neurologic outcomes by inhibiting cell apoptosis in ischemic brains. TAT-NEP1-40 can be used for research of CNS injuries, such as axonal regeneration and functional recovery after stroke .

HY-P5754A

TAT-NEP1-40 TFA	Apoptosis	Neurological Disease
TAT-NEP1-40 TFA is a BBB-penatrable peptide. TAT-NEP1-40 TFA protects PC12 cells against oxygen and glucose deprivation (OGD), and promotes neurite outgrowth. TAT-NEP1-40 TFA also improves ischemia-induced neurologic outcomes by inhibiting cell apoptosis in ischemic brains. TAT-NEP1-40 TFA can be used for research of CNS injuries, such as axonal regeneration and functional recovery after stroke .

Cat. No.	Product Name	Target	Research Area

HY-P99644

ACT017 1 Publications Verification	Glycoprotein VI	Cardiovascular Disease
ACT017 is a Fab fragment of humanized anti-GPVI monoclonal antibody. ACT017 inhibits collagen-induced platelet aggregation. ACT017 has the potential for the research of acute ischemic stroke .

HY-108841

Raleukin 40+ Cited Publications Kineret; Anakinra	Interleukin Related	Inflammation/Immunology Cancer
Raleukin (AMG-719) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin significantly reduces neutrophil accumulation in blood vessels and brain infarct volume as well as improves motor coordination performance in ischemic stroke mice model. Anakinra can be used to study chronic inflammatory disorders like rheumatoid arthritis and cardiovascular recurrence post-myocardial infarction .

HY-P991604

MLN2201 YFC51.1; LDP-01	Integrin	Inflammation/Immunology
MLN2201 is a humanized monoclonal antibody inhibitor, targeting Integrin β2. MLN2201 inhibits the reperfusion injury after stroke and can be used for inflammatory diseases like ischemic stroke research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0546

Ligustroflavone 1 Publications Verification Nuezhenoside	Structural Classification Flavonoids Oleaceae Classification of Application Fields Flavones Ligustrum lucidum Ait. Source classification Phenols Polyphenols Metabolic Disease Plants Disease Research Fields	CaSR RIP kinase Mixed Lineage Kinase TGF-beta/Smad
Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis .

HY-N3307

(+)-Medioresinol 1 Publications Verification	Cardiovascular Disease Structural Classification Oleaceae Fraxinus mandshurica Rupr. Neurological Disease Classification of Application Fields Source classification Phenols Polyphenols Plants Disease Research Fields	Bacterial Fungal Reactive Oxygen Species (ROS) Apoptosis MMP Interleukin Related PI3K Akt mTOR PPAR PGC-1α Pyroptosis
(+)-Medioresinol is a furofuran-type lignan with antifungal and antibacterial properties. (+)-Medioresinol synergizes with antibiotics to exert antimicrobial and antibiofilm effects. (+)-Medioresinol induces intracellular ROS accumulation and mitochondrial-mediated apoptosis in Candida albicans. (+)-Medioresinol inhibits LPS (HY-D1056)-stimulated IL-12p40 production. (+)-Medioresinol is a PGC-1α activator that protects against endothelial cell pyroptosis in ischemic stroke via the PPARα-GOT1 axis. (+)-Medioresinol can be used in research on fungal and bacterial infection, inflammation, and ischemic stroke .

HY-N0361

Dihydrocapsaicin 2 Publications Verification	Alkaloids Structural Classification Monophenols Capsicum annuum L. Classification of Application Fields Other Alkaloids Source classification Phenols Metabolic Disease Solanaceae Plants Disease Research Fields	TRP Channel Reactive Oxygen Species (ROS) Apoptosis Caspase Bcl-2 Family Akt PI3K
Dihydrocapsaicin, a capsaicin, is a potent and selective TRPV1 (transient receptor potential vanilloid channel 1) agonist. Dihydrocapsaicin reduces AIF, Bax, and Caspase-3 expressions, and increased Bcl-2, Bcl-xL and p-Akt levels. Dihydrocapsaicin enhances the hypothermia-induced neuroprotection following ischemic stroke via PI3K/Akt regulation in rat .

HY-N9347

Stepharine 3 Publications Verification	Cardiovascular Disease Alkaloids other families Classification of Application Fields Source classification Plants Isoquinoline Alkaloids Disease Research Fields	Toll-like Receptor (TLR)
Stepharine, an natural alkaloid, directly interactes with TLR4 and binds to the TLR4/MD2 complex (TLR4 inhibitor). Stepharine possesses anti-aging, anti-viral and anti-hypertensive effects .

HY-B1065

Aceglutamide α-N-Acetyl-L-glutamine; N2-Acetylglutamine	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Keap1-Nrf2 Akt ASK1 Apoptosis
Aceglutamide (α-N-Acetyl-L-glutamine; N2-Acetylglutamine) is a neuroprotectant that can penetrate the blood-brain barrier. Aceglutamide can enhance the antioxidant systems of glutathione (GSH), thioredoxin (Trx) and Nrf2. Aceglutamide also inhibits ASK1 and TRAF1, activates the Akt/Bcl-2 anti-apoptotic pathway, enhances the activity of antioxidant enzymes and reduces oxidative damage. Aceglutamide can improve neurological deficits after cerebral ischemia, reduce infarct volume, and inhibit neuronal apoptosis, especially substantia nigra dopaminergic neurons. Aceglutamide can reduce cerebral ischemia/reperfusion injury, improve motor dysfunction, and is used in ischemic stroke-related research .

HY-N4205

Tetrahydropiperine	Alkaloids Piperidine Alkaloids Structural Classification Classification of Application Fields Source classification Piperaceae Plants Disease Research Fields Piper nigrum Linn. Cancer	Cytochrome P450
Tetrahydropiperine is an orally effective, selective inhibitor of NF-κB and MAPKs<、b>, and an activator of the PI3K/Akt/mTOR<、b> pathway. Tetrahydropiperine reduces the production of pro-inflammatory cytokines such as TNF-α, IL-6, and nitric oxide (NO) by inhibiting the nuclear translocation of NF-κB and the phosphorylation of MAPKs such as ERK, JNK, and p38. At the same time, Tetrahydropiperine inhibits excessive autophagy by activating the PI3K/Akt/mTOR pathway, protecting neurons from oxidative damage. Tetrahydropiperine has anti-inflammatory, anti-apoptotic, and neuroprotective effects, and is mainly used in the study of inflammatory diseases (such as endotoxemia, arthritis) and neurological diseases such as ischemic stroke .

HY-N13251

Verbena Extract	Cardiovascular Disease Classification of Application Fields Verbenaceae Source classification Plants Disease Research Fields	Others
Verbena Extract is a verbena extract. Verbena Extract is a potential anti-ischemic stroke agent, and its mechanism may be related to IL17A-mediated neuroinflammation regulation. .

HY-N0546R

Ligustroflavone (Standard) Nuezhenoside (Standard)	Structural Classification Flavonoids Oleaceae Flavones Ligustrum lucidum Ait. Source classification Phenols Polyphenols Plants	Reference Standards CaSR RIP kinase Mixed Lineage Kinase TGF-beta/Smad
Ligustroflavone (Standard) is the analytical standard of Ligustroflavone (HY-N0546). This product is intended for research and analytical applications. Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis .

HY-N0361R

Dihydrocapsaicin (Standard)	Alkaloids Structural Classification Monophenols Capsicum annuum L. Other Alkaloids Source classification Phenols Solanaceae Plants	Reference Standards TRP Channel Reactive Oxygen Species (ROS) Apoptosis Caspase Bcl-2 Family Akt PI3K
Dihydrocapsaicin (Standard) is the analytical standard of Dihydrocapsaicin. This product is intended for research and analytical applications. Dihydrocapsaicin, a capsaicin, is a potent and selective TRPV1 (transient receptor potential vanilloid channel 1) agonist. Dihydrocapsaicin reduces AIF, Bax, and Caspase-3 expressions, and increased Bcl-2, Bcl-xL and p-Akt levels. Dihydrocapsaicin enhances the hypothermia-induced neuroprotection following ischemic stroke via PI3K/Akt regulation in rat .

HY-N8931

Monomethyl lithospermate Lithospermic acid monomethyl ester	Structural Classification Labiatae Source classification Samanea saman (Jacq.) Merr. Phenols Polyphenols Plants	Akt
Monomethyl lithospermate activates the PI3K/AKT pathway, which plays a protective role in nerve injury. Monomethyl lithospermate can improve the survival ability of SHSY-5Y cells, inhibit the breakdown of mitochondrial membrane potential (MMOP) and inhibit cell apoptosis. Monomethyl lithospermate also reduced the level of oxidative stress in the brain tissue of rats with middle artery occlusion (MCAO) and improved nerve damage in rats with ischemic stroke (IS) .

HY-B1065R

Aceglutamide (Standard) α-N-Acetyl-L-glutamine (Standard); N2-Acetylglutamine (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Reference Standards Keap1-Nrf2 Akt ASK1 Apoptosis
Aceglutamide (α-N-Acetyl-L-glutamine; N2-Acetylglutamine) (Standard) is the analytical standard of Aceglutamide (HY-B1065). This product is intended for research and analytical applications. Aceglutamide (α-N-Acetyl-L-glutamine; N2-Acetylglutamine) is a neuroprotectant that can penetrate the blood-brain barrier. Aceglutamide can enhance the antioxidant systems of glutathione (GSH), thioredoxin (Trx) and Nrf2. Aceglutamide also inhibits ASK1 and TRAF1, activates the Akt/Bcl-2 anti-apoptotic pathway, enhances the activity of antioxidant enzymes and reduces oxidative damage. Aceglutamide can improve neurological deficits after cerebral ischemia, reduce infarct volume, and inhibit neuronal apoptosis, especially substantia nigra dopaminergic neurons. Aceglutamide can reduce cerebral ischemia/reperfusion injury, improve motor dysfunction, and is used in ischemic stroke-related research .

HY-30004

1-Aminocyclopropane-1-carboxylic acid	Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
1-Aminocyclopropane-1-carboxylic acid is an endogenous metabolite. In the presence of low concentrations (1 μM) of glutamate, 1-Aminocyclopropane-1-carboxylic acid acts as a small molecule agonist of NMDA receptors with an EC50 of 0.7-0.9 μM. At high concentrations (10 μM) of glutamate, 1-Aminocyclopropane-1-carboxylic acid acts as a competitive antagonist of NMDA receptors with an EC50 of 81.6 nM. 1-Aminocyclopropane-1-carboxylic acid exerts neuroprotective activity by moderately activating NMDA receptors to prevent neuronal cell death in ischemic animal models. Additionally, 1-Aminocyclopropane-1-carboxylic acid is an antagonist of NMDA receptors, inducing blood pressure reduction and antioxidant effects in stroke-prone hypertensive rats. 1-Aminocyclopropane-1-carboxylic acid enhances object recognition memory and cognitive flexibility dependent on the prefrontal cortex, but does not affect impulsivity nor exhibit an antipsychotic-like profile. 1-Aminocyclopropane-1-carboxylic acid shows promise for research in the field of neurotoxicity. .

HY-30004R

1-Aminocyclopropane-1-carboxylic acid (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Reference Standards Endogenous Metabolite
1-Aminocyclopropane-1-carboxylic acid (Standard) is the analytical standard of 1-Aminocyclopropane-1-carboxylic acid. This product is intended for research and analytical applications. 1-Aminocyclopropane-1-carboxylic acid is an endogenous metabolite. In the presence of low concentrations (1 μM) of glutamate, 1-Aminocyclopropane-1-carboxylic acid acts as a small molecule agonist of NMDA receptors with an EC50 of 0.7-0.9 μM. At high concentrations (10 μM) of glutamate, 1-Aminocyclopropane-1-carboxylic acid acts as a competitive antagonist of NMDA receptors with an EC50 of 81.6 nM. 1-Aminocyclopropane-1-carboxylic acid exerts neuroprotective activity by moderately activating NMDA receptors to prevent neuronal cell death in ischemic animal models. Additionally, 1-Aminocyclopropane-1-carboxylic acid is an antagonist of NMDA receptors, inducing blood pressure reduction and antioxidant effects in stroke-prone hypertensive rats. 1-Aminocyclopropane-1-carboxylic acid enhances object recognition memory and cognitive flexibility dependent on the prefrontal cortex, but does not affect impulsivity nor exhibit an antipsychotic-like profile. 1-Aminocyclopropane-1-carboxylic acid shows promise for research in the field of neurotoxicity. .

Cat. No.	Product Name	Chemical Structure

HY-N0361S

Dihydrocapsaicin-d3

Dihydrocapsaicin-d₃ is the deuterium labeled Dihydrocapsaicin (HY-N0361) . Dihydrocapsaicin, a capsaicin, is a potent and selective TRPV1 (transient receptor potential vanilloid channel 1) agonist. Dihydrocapsaicin reduces AIF, Bax, and Caspase-3 expressions, and increased Bcl-2, Bcl-xL and p-Akt levels. Dihydrocapsaicin enhances the hypothermia-induced neuroprotection following ischemic stroke via PI3K/Akt regulation in rat .

HY-151546S

MRS4596-d4
MRS4596-d₄ is the deuterium labeled MRS4596 (HY-151546). MRS4596 is a potent and selective P2X4 receptor antagonist with an IC₅₀ value of 1.38 μM for human P2X4 receptor. MRS4596 has neuroprotective and neuro-rehabilitative activities in ischemic stroke model. MRS4596 can be used in research of ischemic stroke .

HY-151547S

MRS4719-d3

MRS4719-d₃ is the deuterium labeled MRS4719 (HY-151547). MRS4719 is a potent P2X4 receptor antagonist with an IC₅₀ value of 0.503 μM for human P2X4 receptor. MRS4719 can reduce infarct volume and reduce brain atrophy, showing neuroprotective and neuro-rehabilitative activities in ischemic stroke model. MRS4719 also reduces ATP-induced [Ca ²⁺]_i influx in primary human monocyte-derived macrophages. MRS4719 can be used to research ischemic stroke .

Cat. No.	Product Name		Classification